Zenas Biopharma Inc
NASDAQ:ZBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Z
|
Zenas Biopharma Inc
NASDAQ:ZBIO
|
US |
Cash Flow Statement
Cash Flow Statement
Zenas Biopharma Inc
| Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||
| Net Income |
(167)
|
(32)
|
(37)
|
(46)
|
(55)
|
(129)
|
(157)
|
(163)
|
(177)
|
(190)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Stock-Based Compensation |
2
|
3
|
4
|
4
|
5
|
6
|
11
|
10
|
20
|
24
|
|
| Other Non-Cash Items |
57
|
14
|
15
|
15
|
6
|
8
|
12
|
15
|
19
|
30
|
|
| Change in Working Capital |
(3)
|
(14)
|
(8)
|
7
|
15
|
24
|
25
|
10
|
10
|
2
|
|
| Cash from Operating Activities |
(113)
N/A
|
(32)
+71%
|
(31)
+5%
|
(24)
+23%
|
(34)
-43%
|
(97)
-187%
|
(120)
-24%
|
(138)
-15%
|
(148)
-8%
|
(158)
-7%
|
|
| Investing Cash Flow | |||||||||||
| Capital Expenditures |
(2)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(5)
|
|
| Other Items |
0
|
0
|
0
|
0
|
0
|
(27)
|
(30)
|
(117)
|
(229)
|
(157)
|
|
| Cash from Investing Activities |
(2)
N/A
|
(1)
+51%
|
(0)
+98%
|
(0)
-129%
|
(0)
-90%
|
(27)
-36 162%
|
(31)
-14%
|
(117)
-282%
|
(229)
-96%
|
(162)
+29%
|
|
| Financing Cash Flow | |||||||||||
| Net Issuance of Common Stock |
59
|
59
|
0
|
0
|
179
|
413
|
419
|
419
|
243
|
9
|
|
| Net Issuance of Debt |
0
|
20
|
20
|
0
|
0
|
0
|
0
|
0
|
0
|
75
|
|
| Other |
0
|
0
|
0
|
(1)
|
(1)
|
(2)
|
(6)
|
0
|
0
|
(8)
|
|
| Cash from Financing Activities |
59
N/A
|
79
+34%
|
20
-75%
|
19
-3%
|
197
+914%
|
411
+109%
|
413
+0%
|
414
+0%
|
238
-43%
|
76
-68%
|
|
| Change in Cash | |||||||||||
| Effect of Foreign Exchange Rates |
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
(0)
|
(0)
|
|
| Net Change in Cash |
(55)
N/A
|
46
N/A
|
(10)
N/A
|
(4)
+61%
|
163
N/A
|
288
+76%
|
263
-9%
|
159
-39%
|
(140)
N/A
|
(245)
-75%
|
|
| Free Cash Flow | |||||||||||
| Free Cash Flow |
(115)
N/A
|
(33)
+71%
|
(31)
+8%
|
(24)
+23%
|
(34)
-43%
|
(97)
-187%
|
(120)
-24%
|
(138)
-15%
|
(148)
-8%
|
(164)
-10%
|
|